Clinical Trial: Trastuzumab Rezetecan + Bevacizumab vs. TAS-102 + Bevacizumab in Pretreated mCRC With HER2 Low/Moderate Expression or HER2 Positivity With RAS/BRAF Mutation

U.S., Nov. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07926477) titled 'Trastuzumab Rezetecan + Bevacizumab vs. TAS-102 + Bevacizumab in Pretreated mCRC With HER2 Low/Moderate Expression or HER2 Positivity With RAS/BRAF Mutation' on Oct. 20.

Brief Summary: This is a randomized, open-label, study designed to evaluate the efficacy and safety of trastuzumab rezetecan plus bevacizumab versus trifluridine/tipiracil (FTD/TPI; TAS-102) plus bevacizumab in patients with metastatic colorectal cancer (mCRC) who have failed prior standard chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan and whose tumors show HER2 low-to-moderate expression (IHC 2+ and ISH-negative, or IHC 1+) or HER2 positivity (IHC...